PRECISION CARE
ALWAYS GET HIGH POSITIVE RATES
At Ca-Genome Rx, we leverage the transformative potential of ultra-low-cost genomic and transcriptomic sequencing paired with proprietary genomic biomarkers and advanced machine learning tailored for genomics data. Our mission is to empower oncologists and patients with precise, actionable insights that not only optimize treatment decisions but also enhance survival rates and overall outcomes in the battle against cancer.
Ca-Genome Rx distinguishes itself through its focus on ultra-low-cost sequencing technologies and the development of proprietary genomic biomarkers such as Intragenic Rearrangement Burden (IGR) and Tumor-Associated Antigen Burden (TAB). By integrating these unique biomarkers with proprietary machine learning algorithms, iGenSig-Rx and iGenSig-AI, Ca-Genome Rx delivers unparalleled precision by tailoring actionable insights to the unique genomic landscapes of individual tumors, distinguishing itself as a leader in low-cost omics-based precision oncology.
A RIGHT DECISION
FROM LOW COST OMICS
The introduction of the $100 whole genome sequencer in 2024 brings affordable deep genomic sequencing to the horizon. The field of cancer therapeutics has undergone a profound transformation with the advent of low-cost omics sequencing, yet critical challenges persist. Conventional NGS-based precision oncology services, such as cancer mutation gene panels, often fall short in providing comprehensive coverage, with a vast majority of patients receiving inconclusive or non-actionable results, leaving significant gaps in delivering effective treatment options.
Ca-Genome Rx is resolutely committed to addressing these gaps by advancing the boundaries of genomic and multi-omic analysis, empowering oncologists with highly personalized and actionable treatment strategies designed to optimize patient outcomes. Ca-Genome Rx harnesses the cutting edge ultra-low-cost sequencing technologies to bridge critical gaps in omics-based clinical decision-making. By delivering high-patient coverage with actionable and positive insights, we redefine the standards of precision oncology, ensuring comprehensive support tailored to diverse patient needs. Our transformative approach equips oncologists with the tools to redefine the standard of care, delivering unparalleled insights and expanding therapeutic possibilities for patients worldwide.
